Crystals of SMAC mimetics as IAP inhibitors and methods for preparing same

Crystals of a SMAC mimetic compound effectively target cIAP1 to overcome cancer cell resistance, providing a therapeutic approach for cancers with apoptotic defects by enhancing apoptosis induction and improving treatment efficacy.

JP7587526B2Active Publication Date: 2024-11-20CHIA TAI TIANQING PHARMA GRP CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2021566285
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-10
Filing Date
2020-05-09
Publication Date
2024-11-20
Estimated Expiration
2040-05-09

AI Technical Summary

Technical Problem

Cancer cells often exhibit defects in apoptotic mechanisms, leading to resistance to chemotherapy, radiotherapy, and immunotherapy, necessitating a therapeutic approach that targets key negative regulators of apoptosis, such as IAPs, to induce apoptosis effectively.

Method used

Development of crystals of a SMAC mimetic compound (formula I) with specific crystalline compositions for cIAP1 inhibition, which can be formulated into pharmaceutical compositions for administering therapeutically effective amounts to treat cancers associated with cIAP1 overexpression.

Benefits of technology

The crystals demonstrate high stability, cIAP1 inhibitory activity, and good pharmacokinetic properties, showing efficacy in treating cancers like triple-negative breast cancer with enhanced apoptosis induction and reduced resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587526000013
    Figure 0007587526000013
  • Figure 0007587526000014
    Figure 0007587526000014
  • Figure 0007587526000015
    Figure 0007587526000015
Patent Text Reader

Abstract

The present invention provides a crystal of a SMAC mimetic as an IAP inhibitor, a method for producing the same, and a use of the crystal for producing a cancer treatment drug involving cIAP1 inhibition. The crystal of the compound of formula (I) is highly stable, has low hygroscopicity, and has advantages in physical properties, safety, and metabolic stability, making it highly valuable as a drug. [Formula 1] TIFF2022531794000014.tif49126
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims priority from Chinese Patent Application No. 201910389970.8, filed with the State Intellectual Property Office of the People's Republic of China on May 10, 2019, the entire contents of which are incorporated herein by reference.

[0002] [Technical field] The present application is in the field of medicinal chemistry and relates to crystals of SMAC mimetics as IAP inhibitors, a method for preparing the same, and the use of the crystals for the preparation of drugs for the treatment of cancer involving cIAP1 inhibition. [Background technology]

[0003] Programmed cell death plays an important role in regulating cell numbers and removing stressed or damaged cells from normal tissues. In fact, the inherent apoptosis signaling network mechanism in most types of cells provides the main barrier to prevent the development and progression of human cancer. However, all cancer cells have in common that they cannot execute the apoptosis program, and they lack proper apoptosis due to the absence of normal apoptosis mechanisms. Currently, most cancer treatments, including chemotherapy, radiotherapy, and immunotherapy, are effective by indirectly inducing apoptosis in cancer cells. Therefore, the inability of cancer cells to execute the apoptosis program due to defects in normal apoptosis mechanisms is generally related to the improved resistance of cancer cells to apoptosis induced by chemotherapy, radiotherapy, or immunotherapy. Therefore, it is expected that the design of novel anticancer drugs will provide a therapeutic approach by targeting the direct inhibition of key negative regulators that play a key role in cancer cell apoptosis.

[0004] Currently, two important types of negative regulators of apoptosis have been identified: The first type of regulators are the Bcl-2 family proteins, such as the Bcl-2 and Bcl-XL proteins, two effective anti-apoptotic molecules.

[0005] The second type of important negative regulator of apoptosis is the inhibitor of apoptosis proteins (IAPs). IAPs were first expressed from baculovirus to function as an alternative to the P35 protein. These proteins include XIAP, cIAP1, cIAP2, ML-IAP, ILP-2, NAIP, Apollon, and Survivin. Among them, X-linked inhibitor of apoptosis (XIAP) exerts its anti-apoptotic effect by directly inhibiting caspase-3, caspase-7, and caspase-9. cIAPs mainly inhibit apoptosis by blocking the death receptor pathway. When cIAPs are degraded, their substrate NIK (NF-κB-inducing kinase) accumulates without being degraded. The accumulated NIK activates NF-κB via a non-classical pathway, and the activation of NF-κB promotes the secretion of TNFα, which binds to TNF receptor 1 (TNF-R1) to initiate the death receptor pathway. Degradation of cIAPs increases the secretion of receptor interacting protein kinase 1 (RIPK1), which then forms the pro-apoptotic RIPK1-FADD-caspase-8 complex with FADD (Fas-associated death domin) and caspase-8, which then activates caspase-3, causing apoptosis.

[0006] Overexpression of cIAP1 and cIAP2, due to frequent chromosomal amplification of the 11q21-q23 region (containing two genes), has been observed in multiple malignant diseases, including neuroblastoma, renal cell carcinoma, colorectal cancer, gastric cancer, etc. Summary of the Invention [Means for solving the problem]

[0007] In one aspect of the present application, there is provided a crystal of a compound of formula (I).

[0008] [ka]

[0009] In another aspect of the present application, there is provided a crystalline composition of a compound of formula (I), wherein the crystals of said compound of formula (I) constitute at least 50% by weight of said crystalline composition, preferably at least 75%, more preferably at least 90%, and most preferably at least 95%.

[0010] In another aspect of the present application, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a crystal of the compound of formula (I) or a crystalline composition of the compound of formula (I), which may optionally include at least one pharma- ceutically acceptable carrier or other excipient.

[0011] In another aspect of the present application, there is provided a use of the crystal of the compound of formula (I), the crystal composition of the compound of formula (I), or the pharmaceutical composition for the manufacture of a medicament for the treatment of a cancer involving cIAP1 inhibition.

[0012] In another aspect of the present application, there is provided a use of the crystal of the compound of formula (I), the crystal composition of the compound of formula (I) or the pharmaceutical composition for treating a cancer involving cIAP1 inhibition in a mammal.

[0013] In another aspect of the present application, there is provided a method for treating cancer involving cIAP1 inhibition in a mammal, the method comprising administering to a mammal in need thereof a therapeutically effective amount of said crystal of a compound of formula (I), said crystal composition of a compound of formula (I), or said pharmaceutical composition.

[0014] In another aspect of the present application, there is provided a crystal of the compound of formula (I), a crystal composition of the compound of formula (I), or the pharmaceutical composition for treating a cancer involving cIAP1 inhibition in a mammal.

[0015] (Contents of the invention) In one aspect of the present application, there is provided a crystal of a compound of formula (I).

[0016] [ka]

[0017] The crystals according to the present application may be in a non-solvated form or in a solvated form, for example, a hydrate.

[0018] In one embodiment of the present application, the crystal of the compound of formula (I) is Crystal A, and in an X-ray powder diffraction pattern using CuKα radiation, it has characteristic diffraction peaks at 2θ angles of 12.1°±0.200°, 16.1°±0.200°, 18.5°±0.200°, 20.2°±0.200°, 21.3°±0.200° and 23.0°±0.200°.

[0019] In one embodiment of the present application, the X-ray powder diffraction pattern of crystalline A using CuKα radiation has characteristic diffraction peaks at 2θ angles of 12.1°±0.200°, 16.1°±0.200°, 18.5°±0.200°, 18.8°±0.200°, 19.2°±0.200°, 19.8°±0.200°, 20.2°±0.200°, 21.3°±0.200°, 23.0°±0.200°, 26.6°±0.200° and 27.4°±0.200°.

[0020] In one embodiment of the present application, in the X-ray powder diffraction pattern using CuKα radiation of the crystalline A, 2θ angles are 7.0°±0.200°, 8.7°±0.200°, 12.1°±0.200°, 13.2°±0.200°, 13.9°±0.200°, 16.1°±0.200°, 16.7°±0.200°, 18.5°±0.200°, 18.8°±0.200°, 19.7°±0.200°, 20.7°±0.200°, 21.3°±0.200°, 22.7°±0.200°, 23.7°±0.200°, 24.7°±0.200°, 25.7°±0.200°, 26.7°±0.200°, 27.7°±0.200°, 28.7°±0.200°, 29.7°±0.200°, 30.7°±0.200°, 31.7°±0.200°, 32.7°±0.200°, 33.7°±0.200°, 34.7°±0.200°, 35.7°±0.200°, 36.7°±0.200°, 37.7°±0.200°, 38.7°±0.200°, 39.7°±0.200°, 40.7°±0.200°, 41.7°±0.200°, 42.7°±0.200°, 43.7°±0.200°, 44.7 The compound has characteristic diffraction peaks at 19.2°±0.200°, 19.8°±0.200°, 20.2°±0.200°, 21.0°±0.200°, 21.3°±0.200°, 23.0°±0.200°, 24.3°±0.200°, 25.3°±0.200°, 26.6°±0.200° and 27.4°±0.200°.

[0021] In one embodiment of the present application, in the X-ray powder diffraction pattern using CuKα radiation of the crystalline A, 2θ angles are 7.0°±0.200°, 8.7°±0.200°, 12.1°±0.200°, 13.2°±0.200°, 13.9°±0.200°, 16.1°±0.200°, 16.5°±0.200°, 16.7°±0.200°, 18.5°±0.200°, 18.8°±0.200°, 19.2°±0.200°, 20.2°±0.200°, 21.2°±0.200°, 22.2°±0.200°, 23.2°±0.200°, 24.2°±0.200°, 25.2°±0.200°, 26.2°±0.200°, 27.2°±0.200°, 28.2°±0.200°, 29.2°±0.200°, 30.2°±0.200°, 31.2°±0.200°, 32.2°±0.200°, 33.2°±0.200°, 34.2°±0.200°, 35.2°±0.200°, 36.2°±0.200°, 37.2°±0.200°, 38.2°±0.200°, 39.2°±0.200°, 40.2°±0.200°, 41.2°±0.200°, 42.2°±0.200°, 43.2 4°±0.200°, 27.4°±0.200°, and 29.4°±0.200°.

[0022] In one embodiment of the present application, in the X-ray powder diffraction pattern using CuKα radiation of the crystalline A, 2θ angles are 7.0°±0.200°, 8.7°±0.200°, 9.7°±0.200°, 10.6°±0.200°, 11.4°±0.200°, 12.1°±0.200°, 13.2°±0.200°, 13.9°±0.200°, 16.1°±0.200°, 16.5°±0.200°, 17.5°±0.200°, 18.5°±0.200°, 19.5°±0.200°, 20.5°±0.200°, 21.5°±0.200°, 22.5°±0.200°, 23.5°±0.200°, 24.5°±0.200°, 25.5°±0.200°, 26.5°±0.200°, 27.5°±0.200°, 28.5°±0.200°, 29.5°±0.200°, 30.5°±0.200°, 31.5°±0.200°, 32.5°±0.200°, 33.5°±0.200°, 34.5°±0.200°, 35.5°±0.200°, 36.5°±0.200°, 37.5°±0.200°, 38.5°±0.200°, 39.5°±0.200°, 40.5°±0.200°, 41.5° 6.7°±0.200°, 17.5°±0.200°, 18.5°±0.200°, 18.8°±0.200°, 19.2°±0.200°, 19.5°±0.200°, 19.8°±0.200°, 20.2°±0.200°, 21.0°±0.200°, 21.3°±0.200°, 22.5°±0.200°, 23.0°±0.200°, 23.2°±0.200°, 23.8°± 0.200°, 24.3°±0.200°, 24.6°±0.200°, 25.3°±0.200°, 25.8°±0.200°, 26.6°±0.200°, 26.9°±0.200°, 27.4°±0.200°, 28.1°±0.200°, 29.1°±0.200°, 29.4°±0.200°, 30.1°±0.200°, 30.6°±0.200°, 30.8°±0.20 It has characteristic diffraction peaks at 0°, 31.3°±0.200°, 31.8°±0.200°, 32.2°±0.200°, 32.8°±0.200°, 33.7°±0.200°, 34.0°±0.200°, 34.8°±0.200°, 35.5°±0.200°, 36.6°±0.200°, 37.6°±0.200°, 38.6°±0.200° and 39.6°±0.200°.

[0023] In one embodiment of the present application, the peak positions and intensities of characteristic peaks in the X-ray powder diffraction pattern using CuKα radiation of crystalline A of compound of formula (I) are as shown in Table 1.

[0024] [Table 1]

[0025] In one embodiment of the present application, the X-ray powder diffraction pattern using CuKα radiation of crystalline A of compound of formula (I) is as shown in FIG.

[0026] In one embodiment of the present application, the differential scanning calorimetry (DSC) result diagram of Crystal A of compound of formula (I) shows an absorption peak at 202.5°C.

[0027] In one embodiment of the present application, the differential scanning calorimetry (DSC) result diagram of Crystal A of compound of formula (I) has an absorption peak at an onset temperature of 200.8°C.

[0028] In one embodiment of the present application, the differential scanning calorimetry (DSC) result diagram of Crystal A of the compound of formula (I) is as shown in FIG.

[0029] In one embodiment of the present application, the thermogravimetric analysis (TGA) result of Crystal A of the compound of formula (I) is shown in FIG.

[0030] In another aspect of the present application, (a) forming a suspension or solution of a compound of formula (I) in a solvent; (b) heating the suspension or solution to reflux to allow clarification; and (c) filtering the clarified solution while hot, cooling to crystallize, filtering, and drying to obtain crystalline A of compound of formula (I).

[0031] In one embodiment of the present application, the solvent in step (a) is selected from methanol, ethanol, isopropanol, ethyl acetate, acetonitrile, acetone, tetrahydrofuran, water, and a mixed solvent of water and any of the above solvents, preferably methanol, ethanol, isopropanol, or a mixed solvent of any of them with water, and more preferably ethanol.

[0032] In another aspect of the present application, (d) adding the compound of formula (I) to a solvent and mixing it uniformly by ultrasonication to form a suspension or solution; and (e) heating and stirring the suspension or solution in a thermostatic shaker, centrifuging, and drying to obtain crystalline A of compound of formula (I).

[0033] In one embodiment of the present application, the solvent in step (d) is selected from methanol, ethanol, isopropanol, ethyl acetate, acetonitrile, acetone, tetrahydrofuran, water, a mixed solvent of water and any of the above solvents, and is preferably methanol, ethanol, ethyl acetate, acetonitrile, acetone, tetrahydrofuran, water, a mixed solvent of water and methanol, a mixed solvent of water and ethanol, or a mixed solvent of water and acetone. The volume ratio of water to methanol, water to ethanol, or water to acetone is selected from 1:1-5, and is preferably 1:1-3.

[0034] In one embodiment of the present application, the molar volume ratio of the compound of formula (I) to the solvent in step (a) is 1 mmol:1-10 mL, preferably 1 mmol:2-6 mL, and more preferably 1 mmol:2-4 mL.

[0035] In one embodiment of the present application, the molar volume ratio of the compound of formula (I) to the solvent in step (d) is 1 mmol:1-15 mL, preferably 1 mmol:4-10 mL, and more preferably 1 mmol:8-10 mL.

[0036] In one embodiment of the present application, the reflux temperature in step (b) is 60 to 120°C, preferably 80 to 90°C.

[0037] In one embodiment of the present application, the stirring temperature in step (e) is 30 to 50°C, and preferably 40 to 50°C.

[0038] In another aspect of the present application, there is provided a crystalline composition of the compound of formula (I), wherein the crystalline form of the compound of formula (I) constitutes at least 50% by weight of the crystalline composition, preferably at least 75%, more preferably at least 90%, and most preferably at least 95%. The crystalline composition may contain minor amounts of other crystalline or amorphous forms of the compound of formula (I).

[0039] In another aspect of the present application, there is provided a pharmaceutical composition comprising a therapeutically effective amount of a crystal of the compound of formula (I) or a crystalline composition of the compound of formula (I), which may optionally include at least one pharma- ceutically acceptable carrier or other excipient.

[0040] In another aspect of the present application, there is provided a use of the crystal of the compound of formula (I), the crystal composition of the compound of formula (I), or the pharmaceutical composition for the manufacture of a medicament for the treatment of a cancer involving cIAP1 inhibition.

[0041] In another aspect of the present application, there is provided a use of the crystal of the compound of formula (I), the crystal composition of the compound of formula (I) or the pharmaceutical composition for treating a cancer involving cIAP1 inhibition in a mammal.

[0042] In another aspect of the present application, there is provided a method for treating cancer involving cIAP1 inhibition in a mammal, the method comprising administering to a mammal in need thereof a therapeutically effective amount of said crystal of a compound of formula (I), said crystal composition of a compound of formula (I), or said pharmaceutical composition.

[0043] In another aspect of the present application, there is provided a crystal of the compound of formula (I), a crystal composition of the compound of formula (I), or the pharmaceutical composition for treating a cancer involving cIAP1 inhibition in a mammal.

[0044] In one embodiment of the present application, the mammal is a human. In one embodiment of the present application, the cancer involved in cIAP1 inhibition is selected from breast cancer.

[0045] In one embodiment of the present application, the cancer involved in cIAP1 inhibition is selected from triple-negative breast cancer.

[0046] The crystal of the compound of formula (I) according to the present application has excellent effects in at least one of physiological activity, safety, bioavailability, etc., and the crystal A of the compound of formula (I) has high stability, low hygroscopicity, and good cIAP1 inhibitory activity, and is highly valuable as a drug. The crystal A of the compound of formula (I) also has good pharmacokinetic properties, making it suitable for use as a drug, and the pharmacokinetic properties may be measured in preclinical animal tests on SD rats, beagle dogs, etc., or in clinical trials on humans.

[0047] In the present application, the pharmaceutical composition may be in a particular dosage form, and preferred routes of administration include oral administration, parenteral administration (including subcutaneous, intramuscular, and intravenous administration), rectal administration, etc. For example, dosage forms suitable for oral administration include tablets, capsules, granules, powders, pills, powders, tablets, syrups, and suspensions, dosage forms suitable for parenteral administration include aqueous or non-aqueous injection solutions and emulsions, and dosage forms suitable for rectal administration include suppositories using hydrophilic or hydrophobic carriers.

[0048] In this application, the X-ray powder diffraction pattern of the sample is measured under the following conditions: instrument: Bruker D8 ADVANCE X-ray diffractometer, target: CuKα, wavelength: λ=1.54056 Å, 2θ angle range: 3-40°, divergence slit: 0.60 mm, detector slit: 10.50 mm, divergence limiting slit: 7.10 mm, step length: 0.02°, time / step: 0.12 sec, sample rotation speed: 15 rpm, tube voltage and tube current of Cu target: 40 kV and 40 mA.

[0049] In this application, the DSC curve is measured under the following conditions: Apparatus: TA Q2000 differential scanning calorimeter, temperature range: 30-300°C, heating rate: 10°C / min.

[0050] In this application, the TGA curves are measured under the following conditions: Instrument: TA Q5000 Thermogravimetric Analyzer, Temperature Range: 25-300°C, Heating Rate: 10°C / min.

[0051] In addition, in the X-ray powder diffraction pattern, the position of the peak or the relative intensity of the peak may vary depending on the measuring device, measuring method / conditions, etc. In any particular crystal form, the position of the peak may have an error, and the measurement error of the 2θ value may be ±0.2°. Therefore, when identifying various crystal forms, the error should be taken into consideration, and those within the error are included in the scope of the present application.

[0052] In addition, even for the same crystal form, the position of the absorption peak in DSC may differ depending on the measurement device, measurement method / conditions, etc. For any particular crystal form, the position of the absorption peak may have an error, and the error may be ±5° C. Therefore, when determining various crystal forms, the error should be taken into consideration, and those within the error are included in the scope of the present application.

[0053] In addition, even for the same crystal form, the position of the weight loss temperature in TGA may differ depending on the measurement device, measurement method / conditions, etc. For any particular crystal form, the position of the weight loss temperature may have an error, and the error may be ±5° C. Therefore, when determining various crystal forms, the error should be taken into consideration, and those within the error are included in the scope of the present application.

[0054] (Definitions and Explanations) As used in the specification and claims of this application, the following terms have the following meanings unless otherwise specified.

[0055] "Mammals" includes humans, domestic animals such as laboratory mammals and pets (eg, cats, dogs, pigs, sheep, cows, ovine, goats, horses, rabbits), and non-domestic mammals such as wild mammals.

[0056] The term "pharmaceutical composition" refers to a formulation comprising a compound of the present application and a vehicle generally accepted in the art for delivering a physiologically active compound to a mammal, e.g., a human. The vehicle includes all pharmaceutically acceptable carriers that can be used. A pharmaceutical composition is a compound that is easily administered to a living body.

[0057] The term "therapeutically effective amount" refers to a sufficient dose of a drug or preparation to obtain a desired effect without toxicity. The effective amount varies from person to person, and is related to the age and general condition of the subject, and is also related to the active ingredient, and the appropriate effective amount can be determined by a person skilled in the art through routine testing in each case.

[0058] In this application, the term "pharmaceutical acceptable carrier" refers to a carrier that is administered together with an active ingredient, does not cause obvious irritation to the body, and does not impair the physiological activity or properties of the active compound. For other information on carriers, refer to Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005), the contents of which are incorporated herein by reference.

[0059] In the present application, "room temperature" refers to 20°C to 30°C. [Brief description of the drawings]

[0060] [Figure 1] FIG. 1 is an X-ray powder diffraction (XRPD) pattern of Crystal A of compound of formula (I) in Example 1. [Diagram 2] FIG. 2 is a diagram showing the results of differential scanning calorimetry (DSC) of Crystal A of the compound of formula (I) according to Example 1. [Diagram 3] FIG. 3 is a graph showing the results of thermogravimetric analysis (TGA) of Crystal A of the compound of formula (I) according to Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0061] The following specific examples are provided to enable those skilled in the art to more clearly understand and practice the present application, which are not to be construed as limitations on the scope of the present application, but are merely illustrative and representative examples of the present application.

[0062] The intermediate compounds herein can be prepared by a variety of synthetic methods familiar to those skilled in the art, including the specific embodiments described below, combinations thereof with other chemical synthetic methods, and alternative permutations familiar to those skilled in the art. Preferred embodiments include, but are not limited to, the examples described herein.

[0063] The chemical reactions according to the specific embodiments of the present application are carried out in a suitable solvent, which should be compatible with the chemical transformations according to the present application and with the reagents and materials used. In order to obtain the compounds of the present application, those skilled in the art may make modifications or selections in the synthetic steps or reaction processes in light of the existing embodiments.

[0064] All solvents used in this application are commercially available and can be used without further purification. EXAMPLES

[0065] Example 1: Preparation of Crystal A of Compound of Formula (I)

[0066] [ka]

[0067] Step 1: Add dichloromethane (16.0L) to the reaction kettle, lower the temperature to 0°C, add compound 1 (2.0kg, 9.94mol, 1.0Eq) and stir, add triethylamine (4.42L, 29.81mol, 3.0Eq), 4-dimethylaminopyridine (61.00g, 496.86mmol, 0.05Eq), add p-toluenesulfonyl chloride (2.18kg, 11.43mol, 1.15Eq) in several portions, control the internal temperature to 0-10°C, add dichloromethane (4L) to the reaction kettle, raise the temperature to 20°C and continue stirring for 16 hours. Water (20 L) was added to the reaction kettle, stirred for 5 minutes, allowed to stand and separated, the aqueous phase was removed, and the organic phase was washed with 10% aqueous citric acid solution (15.0 L*2) and brine (15.0 L*2), dried over anhydrous sodium sulfate (2.0 kg) for 1 hour, filtered, and the filtrate was transferred to a rotary evaporator and concentrated to obtain compound 2. 1 H NMR (400MHz, DMSO-d 6 )δ7.78(br d,J=8.2Hz,2H),7.47(br d,J=7.9Hz,2H),4.13-3.93(m,2H),3.92-3.81(m,1H),3.22-3.11(m,2H ),1.96-1.80(m,2H),1.74-1.65(m,2H),1.40(s,3H),1.38-1.23(m,9H).

[0068] Step 2: Add dichloromethane (1.30L) and compound 3 (1.28kg, 8.49mol, 1.0Eq) to a dry reaction kettle, stir and dissolve, lower the temperature, and cool until the internal temperature is 0℃. Under nitrogen gas protection, add acetyl chloride (606.0mL, 8.49mol, 1.0Eq) dropwise over 30 minutes. Then, add 1M diethylaluminum chloride n-hexane solution (8.50L, 8.49mol, 1.0Eq) dropwise to the reaction kettle, control the internal temperature to 0-5℃, dropwise over 3 hours, and react for 1 hour. The reaction mixture was slowly poured into ice water (20.0 L) with stirring in several portions, and a large amount of red solid precipitated. The mixture was quenched and transferred to a rotary evaporator and concentrated at 30°C to remove dichloromethane and n-hexane. 2-Methyltetrahydrofuran (20.0 L) was added to the residue, which was then transferred to a separatory apparatus and stirred for 15 minutes. The aqueous phase was removed, and the organic phase was washed with salt water (20 L*2) and anhydrous sodium sulfate (3.0 L). The mixture was dried on a 50-kg column, filtered, the cake was washed with 2-methyltetrahydrofuran (2 L), the filtrate was transferred to a rotary evaporator and concentrated, the residue was transferred to a 50-L reaction kettle, ethyl acetate:n-heptane (V:V) = 1:1 (10.0 L) was added and stirred for 10 hours, filtered, the cake was rinsed with ethyl acetate:n-heptane (V:V) = 1:1 (300 mL), sucked dry, and transferred to an oven and dried under reduced pressure at 35 °C to obtain compound 4. 1 H NMR (400MHz, DMSO-d 6 )δ12.10(br s,1H),8.38(d,J=3.2Hz,1H),8.16(d,J=2.2Hz,1H),7.50(d,J=8.7Hz,1H),7.23(dd,J=8.6,2.1Hz,1H),2.46(s,3H).

[0069] Step 3: Under nitrogen gas protection, N,N-dimethylacetamide (6.0 L) was added to the reaction kettle, and compound 2 (3.95 kg, 11.12 mol, 1.30 Eq) and compound 4 (1.73 kg, 8.56 mol, 1.0 Eq) were added at 25°C. Cesium carbonate (4.18 kg, 12.85 mol, 1.50 Eq) was added in several portions over 10 minutes. The walls of the reaction kettle were washed with N,N-diethylacetamide (1.0 L), and the temperature was raised to 80-85°C for 16 hours. The temperature was lowered to 25°C, and the reaction solution was slowly added with water (30L) and ethyl acetate (20L), stirred, transferred to a separatory apparatus for separation, the aqueous phase was extracted once with ethyl acetate (10.0L), the organic phases were combined, washed with water (15.0L*2) and brine (15.0L*2), dried over anhydrous sodium sulfate (3.0kg) for 1 hour, filtered, the cake was rinsed with ethyl acetate (2.0L), and the filtrate was transferred to a rotary evaporator and concentrated to obtain a crude product, which was transferred to a reaction kettle, added with ethyl acetate:n-heptane (V:V) = 1:2 (9.0L), stirred for 2 hours, filtered, the cake was rinsed with ethyl acetate:n-heptane (V:V) = 1:2 (500mL), sucked dry, transferred to an oven and dried under reduced pressure at 35°C to obtain compound 5. 1 H NMR (400MHz, DMSO-d 6 )δ8.43-8.28(m,1H),8.17(s,1H),7.74-7.52(m,1H),7.27(br s,1H),4.40-4.05(m,3H),3.31-3.11(m,2H),2.50-2.35(m,3H),1.90-1.69(m,4H),1.39(br d,J=6.7Hz,5H),1.08(br s,4H).

[0070] Step 4: Ethyl acetate (16.5L) and compound 5 (1.65kg, 4.38mol, 1.0Eq) were added to a dry reaction kettle and stirred to dissolve, the temperature was lowered and cooled until the internal temperature reached 0℃, and a freshly prepared hydrochloric acid-ethyl acetate solution (15.0L, 4.0mol / L) was added dropwise over 1 hour, and the temperature was returned to room temperature of 20-30℃ for 16 hours of reaction. The reaction solution was filtered, the cake was rinsed with ethyl acetate (5L*2), and the cake was sucked dry to obtain a crude product, which was suspended in ethyl acetate and stirred for 4 hours. Compound 6 was obtained by filtration and drying. 1 H NMR (400MHz, DMSO-d 6 )δ10.00(br s,1H),9.54(br s,1H),8.76(s,1H),8.16(d,J=1.8Hz,1H),7.84(d,J=8.8Hz,1H),7.30(dd,J=8.7,1.8Hz,1H),4.80-4.72(m,1H),4.62(br d,J=5.4Hz,1H),3.92(br s, 1H), 3.27 (br d, J=6.8Hz, 1H), 3.18-3.00 (m, 1H), 2.44 (s, 3H), 2.17-1.63 (m, 4H).

[0071] Step 5: Compound 7 (2.13 kg, 8.30 mol, 1.05 Eq) and N,N-dimethylformamide (12.50 L) were added to the reaction kettle in this order, the temperature of the reaction kettle was adjusted to 0-10 ° C, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (3.15 kg, 8.30 mol, 1.05 Eq) was added to obtain a white suspension, N,N-diisopropylethylamine (3.06 kg, 23.71 mol, 3.0 Eq) was added dropwise, and the internal temperature was controlled to 10 ° C or less, during which the solid gradually dissolved to obtain a clear solution. After the dropwise addition was completed, the internal temperature was controlled to 5-10 ° C, and the reaction was allowed to proceed for 30 minutes with stirring. Compound 6 (2.50 kg, 7.90 mol, 1.0 Eq) was added in several portions, and the internal temperature was controlled at 5-10°C, during which white smoke was generated. After the dropwise addition was completed, the temperature was gradually raised to 25-30°C, and the reaction was carried out for 1.5 hours. With stirring, half of the reaction solution was slowly added dropwise to a reaction kettle containing water (30.0 L), and a large amount of solid precipitated. After stirring for 30 minutes, the reaction solution was filtered with suction, and the cake was dried by suction, and the remaining half of the reaction solution was treated in the same manner. Both cakes were dried under vacuum at 50°C until the weight was constant, and compound 8 was obtained. 1 H NMR (400MHz, DMSO-d 6 )δ8.47-8.41(m,1H),8.15(d,J=2.1Hz,1H),7.97-7.91(m,1H),7.32(dd,J=8.7,2.0Hz,1H),6.87(br d,J=8.4Hz,1H),4.49-4.30(m,2H),4.15-3.89(m,2H),3.62(br dd,J=8.0,5.0Hz,2H),2.44(s,3H),2.17-1.97(m,1H),1.96-1.85(m,1H),1.78-1.52(m,9H),1.38-1.31(m,9H),1.20-1.06(m,4H).

[0072] Step 6: Ethyl acetate (17.70 L) was added to a 50 L reaction kettle, the temperature of the reaction kettle was adjusted to 0-5°C, and compound 8 (1.70 kg, 3.37 mol, 1.0 Eq) was added to obtain a white suspension, and a hydrochloric acid-ethyl acetate solution (17.70 L, 4 mol / L, 21.0 Eq) prepared freshly was added using a peristaltic pump, during which the solid gradually dissolved to obtain a reddish brown solution. After the dropwise addition was completed, the temperature was gradually raised to 10-25°C and the reaction was continued for 2.5 hours, during which a large amount of reddish brown solid precipitated. The reaction solution was filtered, and the cake and the solid on the kettle wall were dissolved with methanol (7.0 L), and the organic phase was transferred to a rotary evaporator and concentrated under reduced pressure to obtain a solid, which was suspended in ethyl acetate (8.85 L) and stirred overnight. The mixture was filtered, and the cake was dried under vacuum at 35-45°C until the weight was constant to obtain compound 9. 1 H NMR (400MHz, DMSO-d 6 )δ8.50(s,1H),8.30(br d,J=3.1Hz,3H),8.15(d,J=2.1Hz,1H),7.89(d,J=8.8Hz,1H),7.31(dd,J=2.1,8.7H z,1H),4.56-4.45(m,1H),4.45-4.36(m,1H),4.15(dd,J=13.8,8.3Hz,1H),3.86(br t,J=5.1Hz,1H),3.70-3.62(m,1H),3.61-3.56(m,1H),2.44(s,3H),2.19-2.03(m,1H),1.96-1.87(m,1H),1.83-1.66(m,5H),1.60(br d,J=10.3Hz,3H),1.14-0.93(m,4H).

[0073] Step 7: N,N-dimethylformamide (11.88L) was added to the reaction kettle, and the temperature of the reaction kettle was adjusted to 0-5°C. Compound 10 (1.36kg, 6.71mol, 1.05Eq) and O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (2.54kg, 6.71mol, 1.05Eq) were added, and the solid was partially dissolved to obtain a white suspension. N,N-diisopropylethylamine (2.48kg, 19.16mol, 3.0Eq) was added dropwise, and the temperature of the reaction kettle was controlled to 0-5°C. The solid was gradually dissolved to obtain a clear liquid. After the dropwise addition was completed, the temperature of the reaction kettle was controlled at 0-5°C and the reaction was continued for 30 minutes. Compound 9 (2.9 kg, 6.39 mol, 1.0 Eq) was slowly added, during which white smoke was generated and significant heat was released. The reaction temperature was controlled at 0-5°C by controlling the rate of addition of the raw materials. After the dropwise addition was completed, the temperature was raised to 25-30°C and the reaction was continued for 23 hours. The reaction solution was treated in five batches, and the reaction solution (about 5.0 L) was added dropwise to 35.0 L of water while stirring, resulting in the precipitation of a large amount of white solid. The reaction solution was stirred for 30 minutes, filtered, and the cake was dried by suction, and the cake was combined. The cake and the solid on the kettle wall were dissolved in ethyl acetate (30.0 L), then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain compound 11. 1 H NMR (400 MHz, CDCl 3 )δ8.34(d,J=2.0Hz,1H),7.73(s,1H),7.67(br d,J=8.7Hz,1H),7.29-7.22(m,1H),6.78(br s,1H),4.78-4.45(m,4H),3.88-3.55(m,4H),2.84-2.76(m,3H),2.50(s,3H),2.06-1.94(m,2H),1.73(br d,J=10.3Hz,6H),1.51(s,9H),1.39(d,J=6.7Hz,2H),1.33(br d,J=7.0Hz,3H),1.16(br s,4H).

[0074] Step 8: Ethyl acetate (10.0L) was added to the reaction kettle, the temperature of the reaction kettle was adjusted to 0-5°C, and compound 11 (3.84kg, 6.03mol, 1.0Eq) was dissolved in ethyl acetate (9.20L) and added to the reaction kettle. The mixture was added to the hydrochloric acid-ethyl acetate solution (4mol / L, 19.20L) prepared freshly using a peristaltic pump, and the flow rate was set to 0.50L / min. When the dropwise addition was completed, the temperature was gradually raised from room temperature to 25-30°C for 19 hours, and a large amount of solid appeared on the wall of the kettle. Methyl tert-butyl ether (10.0L) was added to the reaction kettle, and the reaction solution was stirred for 2.0 hours, the reaction solution was filtered, and the cake was sucked dry. The cake and the solid on the kettle wall were dissolved with water (30.0L), and when the internal temperature dropped to 5-10°C, it was extracted twice with ethyl acetate (10.0L*2) and the aqueous phase was collected. The aqueous phase was treated in two portions, 15.0 L of water was added to the reaction kettle, and when the internal temperature dropped to 5-10 ° C, a 10% mass fraction aqueous potassium carbonate solution was added dropwise until the pH reached 9, the reaction liquid changed from reddish purple to colorless, and a solid precipitated, which was stirred for 30 minutes and filtered. If the solid was fine-grained, ethyl acetate (1.50 L) was added, stirred for 30 minutes, filtered, the cake was sucked dry, transferred to the reaction kettle, isopropanol was added, and the mixture was stirred for 2.0 hours. The mixture was filtered, and the cake was dried under vacuum at 45 ° C until the weight was constant, to obtain the compound of formula (I). 1 H NMR (400MHz, DMSO-d 6 )δ8.50-8.39(m,1H),8.20-8.09(m,1H),7.96-7.82(m,2H),7.32(dd,J=8. 7,2.1Hz,1H),4.58-4.34(m,3H),4.14-4.02(m,1H),3.79-3.54(m,2H),3.0 6-2.88(m,1H),2.48-2.41(m,3H),2.24-2.13(m,3H),2.09-1.95(m,3H),1 .93-1.85(m,1H),1.79-1.54(m,8H),1.12-1.01(m,6H),0.99-0.86(m,1H).

[0075] Step 9: Ethanol (14.0L) was added to the reaction kettle, stirring was started, and the compound of formula (I) (1.74kg, 3.41mol, 1.0Eq) was added to the reaction kettle, and the solids were not completely dissolved, resulting in a suspension. The temperature of the circulation bath was set to 90°C, and ethanol began to reflux in the kettle, and the solids gradually became clear. After keeping the mixture warm for 15 minutes, it was filtered while still hot, and the filtrate was transferred to the reaction kettle and the temperature was gradually lowered to room temperature, at which point a large amount of solids precipitated. The reaction solution was filtered, and the cake was dried under vacuum at 35-45°C until the weight was constant, to obtain crystal A of the compound of formula (I). 1 H NMR (400MHz, DMSO-d 6 )δ8.47-8.39(m,1H),8.19-8.08(m,1H),7.97-7.67(m,2H),7.38-7.20 (m,1H),4.59-4.29(m,3H),4.17-4.00(m,1H),3.63(td,J=7.6,3.8Hz, 2H),2.97(q,J=6.8Hz,1H),2.47-2.39(m,3H),2.24-2.14(m,3H),2.11 -1.96(m,2H),1.94-1.81(m,1H),1.78-1.49(m,8H),1.25-0.87(m,8H).

[0076] Example 2: Preparation of Crystal A of Compound of Formula (I) Approximately 50 mg of each compound of formula (I) was weighed and added to a 1.5 mL liquid storage vial, and an appropriate amount of solvent or solvent mixture was added (see Table 2), followed by uniform mixing or dissolution by ultrasonic waves. The suspension sample was placed in a thermostatic shaker and stirred at 40° C. in the dark for 60 hours. The liquid sample was then centrifuged at high speed, and the solid was placed in a vacuum oven at 35° C. after centrifugation and dried overnight to obtain a dried sample, which was then subjected to XRPD measurement.

[0077] [Table 2]

[0078] Experimental Example 1: Hygroscopicity test of crystalline A of compound of formula (I) Test conditions: Instrument model number: SMSDVS Advantage Dynamic Gas Adsorption Instrument (DVS).

[0079] Test conditions: Crystal A (10 to 15 mg) of the compound of formula (I) was placed in a DVS sample pan and the test was performed.

[0080] The DVS parameters are: Temperature: 25℃.

[0081] Equilibrium: dm / dt=0.01% / min (minimum 10min, maximum 180min). Drying: Dry for 120 minutes under 0% RH.

[0082] RH(%) measurement gradient: 10%. RH(%) measurement gradient range: 0%~90%~0%.

[0083] For the evaluation criteria of moisture absorption, see Table 3.

[0084] [Table 3]

[0085] Note: *Weight increase due to moisture absorption at 25℃ / 80%RH. Experimental results: The weight gain of crystalline A of the compound of formula (I) due to moisture absorption at 25° C. and 80% RH was 0.72%.

[0086] Experimental conclusion: Crystal A of compound of formula (I) is slightly hygroscopic, easy to store, and not prone to deliquescence, deformation, mold, etc., making it highly valuable as a medicine.

[0087] Experimental Example 2: Stability test of crystalline A of compound of formula (I) Testing Method: Influence factor experiment: 12 parts of crystal A of compound of formula (I) were weighed, each 1.50g, and 3 parts were used for each condition. Each sample was placed in an open weighing bottle, and then placed in a desiccator set to different conditions under high temperature, and then placed in the corresponding stabilization box for investigation. For high humidity conditions, the sample was placed in a stabilization box with the corresponding conditions for investigation.

[0088] Photostability experiment: 4 parts of the crystal A of compound of formula (I) were weighed, each 1.50g, 2 parts were light-exposed samples (one was light-exposed sample for 5 days, the other was light-exposed sample for 10 days), and the remaining 2 parts were control samples (one was light-exposed sample for 5 days, the other was light-exposed sample for 10 days), the light-exposed samples were placed in clean weighing bottles, spread in a single layer, covered with a transparent lid so that the top was not covered, and placed in a light-exposed box to be irradiated with light. The packaging method of the control sample was the same as that of the light-exposed sample, except that the outside of the weighing bottle was covered with aluminum film.

[0089] Long-term accelerated experiment: 22 parts of crystal A of compound of formula (I) were weighed, each weighing 1.50 g. Each sample was placed in a two-layer LDPE bag, and each layer of the LDPE bag was sealed with a buckle, and then placed in an aluminum foil bag and heat-sealed. At the time of detection, the corresponding test sample was taken out and capped, and the sample on day 0 was taken out of the refrigerator and analyzed when it returned to room temperature. XRPD was measured using about 10 mg of the sample. The compound was left to stand under the following conditions, and samples were taken at different times to detect the properties, XRPD, content and related substances. See Table 4 and Table 5 for the test conditions and detection items.

[0090] [Table 4]

[0091] [Table 5]

[0092] Test conclusion: The XRPD measurement results showed that crystalline A of compound of formula (I) was unchanged from day 0, indicating that crystalline A of compound of formula (I) was stable under various test conditions.

[0093] Experimental example 3: Binding experiment of cIAP1 BIR3 and XIAP BIR3 Test materials: Test buffer system (cIAP1 BIR3 or XIAP BIR3 buffer): 0.1 mol / L potassium phosphate, pH 7.5, 0.1% bovine serum albumin, 0.005% Triton X-100, 1% dimethyl sulfoxide.

[0094] Probe: ARPFAQ-K(5-FAM)-NH 2 . the goal: cIAP1-BIR3-his:RBC (catalog no. APT-11-370), the BIR3 domain of human cIAP1 (cIAP1 BIR3, including amino acids 258-363) was expressed and purified from Escherichia coli (E. coli) as a GST-fusion protein.

[0095] XIAP-BIR3-his:RBC (catalog no. APT-11-374), the BIR3 domain of XIAP (XIAP BIR3, including amino acids 255-356) was expressed and purified from E. coli as a GST-fusion protein.

[0096] Reaction conditions: 5 nM ARPFAQ-K(5-FAM)-NH 2 , 20 nM cIAP1 BIR3, 30 nM XIAP BIR3.

[0097] Experimental steps: First, prepare a cIAP1 BIR3 or XIAP BIR3 buffer before use, add 2x cIAP1 BIR3 or XIAP BIR3 solution, and then add the test compound dissolved in 100% DMSO to the cIAP1 BIR3 or XIAP BIR3 buffer by acoustic method, then add 2x probe, mix and incubate for 60 minutes at room temperature in the dark, measure fluorescence polarization and calculate mP value, and finally calculate IC 50 Got the value.

[0098] Experimental results: As shown in Table 6. Test conclusion: The compounds of formula (I) of the present application exhibit good cIAP1 BIR3 binding activity and also show good selectivity for cIAP1 and XIAP.

[0099] Experimental Example 4: In vitro cell activity test Test materials: RPMI 1640 medium (Invitrogen-22400089), fetal bovine serum (Invitrogen-10099141), trypsin (Trypsin), 0.05% EDTA·4Na (Invitrogen-25300062), bioluminescence cell viability detection kit (Promega-G7573), Dulbecco's phosphate buffer (HyClone-SH30028.01B), 384-well plate (Corning-6007680), Envision multilabel analyzer.

[0100] Testing Method: 1. 30 μL of MDA-MB-231 cell suspension containing 250 MDA-MB-231 cells was added to the wells of a 384 microwell plate.

[0101] 2. 20μL of test compound (the highest concentration of test compound was 10μM, the test compounds were diluted 5-fold gradient, and each compound was diluted into 10 concentration gradients) was added, and then the cell culture plate was returned to the carbon dioxide incubator and cultured for 7 days.

[0102] 3. The cell culture plate was left standing horizontally at room temperature for 30 minutes. 4. 20 μL of Promega CellTiter-Glo reagent was added to each well of the cell culture plate.

[0103] 5. After 10 minutes, read on Envision multilabel analyzer. Experimental results: See Table 6.

[0104] Test conclusion: The compounds of formula (I) of the present application have good MDA-MB-231 cell antiproliferative activity.

[0105] [Table 6]

[0106] Experimental Example 5: In vivo efficacy study 1 In vivo efficacy experiments were performed in xenograft (CDX) BALB / c nude mice subcutaneously implanted with a human-derived tumor cell line from a patient with triple-negative breast cancer, MDA-MB-231.

[0107] Testing Procedure: Female BALB / c nude mice, 6-8 weeks old and weighing approximately 18-22 g, were kept in ventilated cages (3 mice per cage) in a pathogen-free special environment. All cages, bedding and water were disinfected before use. All animals were allowed to consume certified standard laboratory animal chow ad libitum. A total of 48 mice were purchased from Shanghai BK Laboratory Animal Co., LTD and used in the experiment. Each mouse was inoculated with tumor cells (10 × 10 in 0.2 mL of phosphate buffer) in the right flank. 6 The tumors were then subcutaneously implanted and allowed to grow. The average tumor volume was approximately 147 mm. 3 The administration of the test compound was started when the tumor volume reached 100 mg / kg. The test compound was orally administered every day at a dose of 30 mg / kg. The tumor volume was measured every 3 days using a two-dimensional measuring instrument caliper, and the volume unit was mm 3 and the formula is: V = 0.5a × b 2where a is the long diameter of the tumor and b is the short diameter. The antitumor effect was determined by dividing the average tumor volume of the compound-treated animals by the average tumor volume of the untreated animals.

[0108] Experimental results: See Table 7. Test conclusion: In the MDA-MB-231 triple-negative breast cancer CDX in vivo efficacy model, the compound of formula (I) of the present application shows good efficacy.

[0109] [Table 7]

[0110] Experimental Example 6: In vivo efficacy study 2 In vivo efficacy experiments were performed in xenograft (CDX) BALB / c nude mice subcutaneously implanted with a human-derived tumor cell line from a patient with triple-negative breast cancer, MDA-MB-231.

[0111] Testing Procedure: Female BALB / c nude mice, 6-8 weeks old and weighing approximately 18-22 g, were kept in ventilated cages (3 mice per cage) in a pathogen-free special environment. All cages, bedding and water were disinfected before use. All animals were allowed to consume certified standard laboratory animal chow ad libitum. A total of 48 mice were purchased from Shanghai BK Laboratory Animal Co., LTD and used in the experiment. Each mouse was inoculated with tumor cells (10 × 10 in 0.2 mL of phosphate buffer) in the right flank. 6 The tumors were then subcutaneously implanted and allowed to grow. The average tumor volume was approximately 110 mm. 3 The administration of the test compound was started when the tumor volume reached 100 mg / kg. The test compound was orally administered every day at a dose of 30 mg / kg. The tumor volume was measured every 3 days using a two-dimensional measuring instrument caliper, and the volume unit was mm 3 and the formula is: V = 0.5a × b 2where a is the long diameter of the tumor and b is the short diameter. The antitumor effect was determined by dividing the average tumor volume of the compound-treated animals by the average tumor volume of the untreated animals.

[0112] Experimental results: see Table 8. Test conclusion: In the MDA-MB-231 triple-negative breast cancer CDX in vivo efficacy model, the compound of formula (I) of the present application shows good efficacy.

[0113] [Table 8]

Claims

1. A crystal of the compound of formula (I). 【Chemistry 1】

2. 2. The crystal of claim 1, which is a crystalline A of the compound of formula (I), and has characteristic diffraction peaks at 2θ angles of 12.1°±0.200°, 16.1°±0.200°, 18.5°±0.200°, 20.2°±0.200°, 21.3°±0.200° and 23.0°±0.200° in an X-ray powder diffraction pattern using CuKα radiation.

3. Crystal A of compound of formula (I) according to claim 2, having characteristic diffraction peaks at 2θ angles of 12.1°±0.200°, 16.1°±0.200°, 18.5°±0.200°, 18.8°±0.200°, 19.2°±0.200°, 19.8°±0.200°, 20.2°±0.200°, 21.3°±0.200°, 23.0°±0.200°, 26.6°±0.200° and 27.4°±0.200° in an X-ray powder diffraction pattern using CuKα radiation.

4. In the X-ray powder diffraction pattern using CuKα radiation, 2θ angles are 7.0°±0.200°, 8.7°±0.200°, 12.1°±0.200°, 13.2°±0.200°, 13.9°±0.200°, 16.1°±0.200°, 16.7°±0.200°, 18.5°±0.200°, 18.8°±0.200°, and 19.2°±0.200°. Crystal A of compound of formula (I) according to claim 3, having characteristic diffraction peaks at 19.8°±0.200°, 20.2°±0.200°, 21.0°±0.200°, 21.3°±0.200°, 23.0°±0.200°, 24.3°±0.200°, 25.3°±0.200°, 26.6°±0.200° and 27.4°±0.200°.

5. In the X-ray powder diffraction pattern using CuKα radiation, 2θ angles are 7.0°±0.200°, 8.7°±0.200°, 12.1°±0.200°, 13.2°±0.200°, 13.9°±0.200°, 16.1°±0.200°, 16.5°±0.200°, 16.7°±0.200°, 18.5°±0.200°, 18.8°±0.200°, 19.2°±0.200°, 19.8°±0.200°, 5. A crystalline A of compound of formula (I) according to claim 4, having characteristic diffraction peaks at 20.2°±0.200°, 21.0°±0.200°, 21.3°±0.200°, 23.0°±0.200°, 23.2°±0.200°, 24.3°±0.200°, 25.3°±0.200°, 26.6°±0.200°, 26.9°±0.200°, 27.4°±0.200° and 29.4°±0.200°.

6. In the X-ray powder diffraction pattern using CuKα radiation, the 2θ angles were 7.0°±0.200°, 8.7°±0.200°, 9.7°±0.200°, 10.6°±0.200°, 11.4°±0.200°, 12.1°±0.200°, 13.2°±0.200°, 13.9°±0.200°, 16.1°±0.200°, 16.5°±0.200°, 16.7°±0.200°, 0.200°, 17.5°±0.200°, 18.5°±0.200°, 18.8°±0.200°, 19.2°±0.200°, 19.5°±0.200°, 19.8°±0.200°, 20.2°±0.200°, 21.0°±0.200°, 21.3°±0.200°, 22.5°±0.2 00°, 23.0°±0.200°, 23.2°±0.200°, 23.8°±0.200°, 24.3°±0.200°, 24.6°±0.200°, 25.3°±0.200°, 25.8°±0.200°, 26.6°±0.200°, 26.9°±0.200°, 27.4°±0.200°, 28.1°±0.200°, 29.1°±0.200°, 29.4°±0.200°, 30.1°±0.200°, 30.6°±0.200°, 30.8°±0.200°, 31.3°±0.200°, 31.8°±0.200°, 32.2°±0.200°, 32.8°±0.200°, 33.7 Crystal A of compound of formula (I) according to claim 5, having characteristic diffraction peaks at 34.0°±0.200°, 34.8°±0.200°, 35.5°±0.200°, 36.6°±0.200°, 37.6°±0.200°, 38.6°±0.200° and 39.6°±0.200°.

7. The compound of formula (I) according to any one of claims 2 to 6, wherein the peak value of the absorption peak is 202.5°C in the differential scanning calorimetry result diagram.

8. The compound of formula (I) according to any one of claims 2 to 6, wherein the onset of the absorption peak is at about 200.8°C in the differential scanning calorimetry result diagram.

9. A crystalline composition, wherein the crystalline compound of formula (I) according to claim 1 accounts for 50% or more by weight of the crystalline composition.

10. The crystalline composition of claim 9, wherein the compound of formula (I) of claim 1 accounts for 90% or more by weight of the crystalline composition.

11. The crystalline composition of claim 9, wherein the compound of formula (I) of claim 1 accounts for 95% or more by weight of the crystalline composition.

12. A pharmaceutical composition comprising a crystal of the compound of formula (I) according to claim 1 or a crystalline composition according to any one of claims 9 to 11.

13. Use of the compound of formula (I) crystal according to claim 1, the crystal composition according to any one of claims 9 to 11, or the pharmaceutical composition according to claim 12, for the manufacture of a drug for the treatment of cancer involving cIAP1 inhibition.

Citation Information

Patent Citations

  • inhibitor of iap

    JP2007532504A

  • iap inhibitor

    JP2008505904A

  • pyrrolidine inhibitor of iap

    JP2008524333A

  • IAP inhibitors

    JP2009544727A

  • Pyrrolidine derivatives as IAP inhibitors

    JP2010506847A